ABT250103P135000
- 0.00
- 0.000.00%
Abbott Laboratories Newsroom
Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt
Catalyst Watch: CES, M&A Votes and the Supreme Court Tackles the TikTok Case
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Abbott Hosts Conference Call for Fourth-Quarter Earnings
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $136
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
How Is The Market Feeling About Abbott Laboratories?
5 MedTech Stocks That Are Poised to Beat the Market in 2025
With 77% Ownership, Abbott Laboratories (NYSE:ABT) Boasts of Strong Institutional Backing
Why Is Abbott Laboratories (ABT) Among Diamond Hill Capital's Top Stock Picks?
Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Express News | Abbott Laboratories announced that it has reached an agreement with Medical Devices company DexCom to resolve all patent disputes between the two parties regarding continuous glucose monitoring devices.
Express News | DexCom and Abbott Laboratories have reached a settlement in the patent litigation.
DexCom, Abbott Agree to Settlement in Patent Litigation
Express News | Abbott: Agreement Will Result in Dismissal of All Pending Cases in Courts, Patent Offices Worldwide - Website
Express News | Abbott: There Are No Financial Payments Associated With Settlement From Either Abbott or Dexcom
Express News | Abbott: Agrees to Global Continuous Glucose Monitoring Litigation Settlement With Dexcom